Axovant Sciences (NASDAQ:AXON) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Other equities research analysts have also recently issued reports about the company. Oppenheimer reissued a “buy” rating and issued a $30.00 target price on shares of Axovant Sciences in a research note on Monday, September 25th. Jefferies Group set a $40.00 target price on Axovant Sciences and gave the company a “buy” rating in a research note on Friday, August 25th. HC Wainwright reissued a “buy” rating and issued a $11.00 target price on shares of Axovant Sciences in a research note on Wednesday, September 27th. Robert W. Baird reissued a “hold” rating and issued a $6.00 target price on shares of Axovant Sciences in a research note on Wednesday, November 1st. Finally, Zacks Investment Research cut Axovant Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. Four analysts have rated the stock with a sell rating, five have issued a hold rating and six have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $14.13.

Shares of Axovant Sciences (AXON) opened at $5.40 on Friday. Axovant Sciences has a 52 week low of $4.60 and a 52 week high of $27.98. The company has a current ratio of 5.94, a quick ratio of 5.94 and a debt-to-equity ratio of 0.34.

Institutional investors have recently made changes to their positions in the stock. Federated Investors Inc. PA acquired a new stake in shares of Axovant Sciences during the second quarter worth $1,408,000. Lord Abbett & CO. LLC acquired a new stake in shares of Axovant Sciences during the second quarter worth $696,000. Bank of New York Mellon Corp grew its stake in shares of Axovant Sciences by 27.0% during the second quarter. Bank of New York Mellon Corp now owns 102,664 shares of the biotechnology company’s stock worth $2,380,000 after purchasing an additional 21,801 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Axovant Sciences during the second quarter worth $47,854,000. Finally, Tocqueville Asset Management L.P. acquired a new stake in shares of Axovant Sciences during the second quarter worth $375,000. 96.93% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Axovant Sciences (AXON) Cut to “Sell” at BidaskClub” was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another site, it was illegally copied and reposted in violation of United States and international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/02/axovant-sciences-axon-cut-to-sell-at-bidaskclub.html.

About Axovant Sciences

Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Analyst Recommendations for Axovant Sciences (NASDAQ:AXON)

Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.